Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gem-CHOP: A randomized phase II study of gemcitabine combined with CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone] with or without rituximab in untreated aggressive non-Hodgkin's lymphoma.

Next Previous
X
Search
Trial Profile

Gem-CHOP: A randomized phase II study of gemcitabine combined with CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone] with or without rituximab in untreated aggressive non-Hodgkin's lymphoma.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 01 Feb 2011 Primary endpoint 'Complete-clinical-response-rate' has not been met.
    • 18 Feb 2009 Results have been reported at the 50th Annual Meeting and Exposition of the American Society of Hematology.
    • 23 Mar 2007 Status changed from recruiting to in progress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top